Business Wire

Virtual Exhibitions of 23 Museums Lands on the Alipay Platform to Enhance Engagement with Mobile-Savvy Audience

18.5.2022 10:46:00 EEST | Business Wire | Press release

Share

On International Museum Day 2022, 4DAGE announced it landed virtual tours and exhibitions of 23 museums, including the historic Henan Museum and Zhejiang Provincial Museum in China and the Hetjens Museum in Germany, through a mini program on Alipay, the leading digital open platform. The collaboration between 4DAGE and Alipay provides China’s mobile-savvy audience an opportunity to better engage with and learn about the museums’ rich histories.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220518005528/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

A large bronze mask from China’s “Sanxingdui Ruins” displayed in the Sichuan Museum’s Bronze Age exhibition; from the virtual tour on the Alipay platform (Photo: Business Wire)

The mini program “Yunshang Mibao” (translated as “treasure hunting on the cloud”) launched on the Alipay platform provides users an immersive museum-visiting experience at their fingertips. They can appreciate the beauty of cultural relics in 3D and have a comprehensive tour of historical collections with Chinese narration.

These virtual exhibitions cover a wide range of subjects spanning 8,000 years of history, including Bronze Age civilization in the Yangtze river valley, dinosaurs in the Mesozoic Era and ceramics in the Rococo period.

“We are delighted to collaborate with museums and the Alipay platform to explore innovative ways to communicate the stories and histories of culture institutions to a wider range of museum and art lovers,” said Shen Ming, Director of International Cooperation from 4DAGE, the VR technology provider for the virtual tours.

“Alipay is committed to supporting the digital operations of brands and merchants to enhance their connection and engagement with consumers in China. Together with our partners, we are exploring digital solutions to meet museums’ evolving needs, including leveraging technology to bring their stories to a younger generation and open new commercialization opportunities,” said Xiaoqi Wang, Head of digital operations for culture and tourism sector at Alipay.

The partnership between 4DAGE and Alipay reflects Alipay’s continued commitment to help museums globally engage and deepen their relationship with China’s growing cultural arts and history community at time when international travel is affected by the COVID-19 pandemic.

To further celebrate this year’s International Museum Day, 28 Chinese museums are issuing newly launched creative digital collectibles on the Alipay mini program and the Topnod app, an Ant Group platform for collecting, exploring, and sharing digital collectibles.

A UNESCO report published in May 2020 showed the global museum industry has been severely impacted by COVID-19 with nearly 90% of museums worldwide closing their doors during the pandemic1. However, less than 20% of museum collections were available online, according to a report by the Network of European Museum Organisations in July 20202. Facing the pressing challenges brought by the pandemic, a growing number of museums start to leverage digital platforms and solutions, including online exhibitions, digital tours, and even livestreaming and blockchain technology powered digital collectibles, to better engage with museum lovers.

Including today’s announcement and a recent collaboration with nine Italian museums, over 2,000 museums have landed on the Alipay platform to enhance their digital operations and better connect with museum lovers. These museums are utilising at least one of the digital tools and services available on Alipay, such as mini programs, lifestyle accounts, and blockchain-powered digital collectibles.

About 4DAGE

Founded in 2014, 4DAGE has been dedicated to the studies and application of artificial intelligence in the field of three-dimensional digital reconstruction. As one of the first 3D digital reconstruction centers in China and one of the pioneering companies in 3D display technologies, 4DAGE provides products and solutions to major museums and expositions globally, including the Palace Museum, Nanchang Han Dynasty Haihunhou Historic Site Museum and World Expo. 4DAGE also serves industries ranging from industrial intelligence and smart city to real estate and new retail.

About Alipay

In the evolving digital era, Alipay has transformed from a payment tool of public trust to an open platform for businesses, institutions, service providers, and other partners. Business partners in various industries utilize Alipay to offer consumers a safe and convenient payment experience. Through digital operation, business partners can communicate and provide various commercial and daily life digital services for their clients via Alipay mini programs, lifestyle accounts, and IoT, along with other tools available. Currently, there have been over 80 million businesses serving more than 1 billion consumers via Alipay’s open platform services.

1 https://cimam.org/documents/102/Museums_around_the_world_in_the_face_of_COVID-19_-_UNESCO_Biblioteca_Digital.pdf
2 https://icom.museum/en/news/online-learning-teaching-digitised-collections/

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Bell Wang
Email: yixing.wl@antgroup.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 12:18:00 EEST | Press release

Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0

FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 11:11:00 EEST | Press release

Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize

Boomi Named One of The Sunday Times Best Places to Work 202622.5.2026 09:00:00 EEST | Press release

Boomi, the data activation company for AI, has today been named one of The Sunday Times Best Places to Work 2026 in the Medium Organisation category. The prestigious annual list, produced by The Sunday Times in partnership with global workplace analytics company WorkL, recognises the UK's finest employers based entirely on direct employee feedback, making it one of the most credible and transparent employer benchmarks in the country. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521069859/en/ Boomi Named One of The Sunday Times Best Places to Work 2026 Boomi's results speak to a workplace culture that goes well beyond industry norms. The company achieved an average employee happiness score of 86%, rated Excellent, with consistent scores across all six dimensions of WorkL's framework. Most strikingly, Boomi's flight risk, the proportion of employees who may be considering leaving, stood at just 3%, against a technology se

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye